5 Value Stocks To Watch In The Basic Materials Sector

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are…

Understanding Value Stocks

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Below is a list of notable value stocks in the basic materials sector:

  1. POSCO Holdings (NYSE:PKX) – P/E: 8.72
  2. Gerdau (NYSE:GGB) – P/E: 3.34
  3. Ferroglobe (NASDAQ:GSM) – P/E: 2.0
  4. Commercial Metals (NYSE:CMC) – P/E: 5.58
  5. Westlake (NYSE:WLK) – P/E: 6.56

This quarter, POSCO Holdings experienced an increase in earnings per share, which was $1.46 in Q3 and is now $1.79. This quarter, Gerdau experienced a decrease in earnings per share, which was $0.51 in Q2 and is now $0.34. The company’s most recent dividend yield sits at 2.7%, which has decreased by 22.56% from 25.26% last quarter.

This quarter, Ferroglobe experienced a decrease in earnings per share, which was $0.64 in Q3 and is now $0.42. Most recently, the company reported a dividend yield of 2.99%, which has increased by 0.88% from last quarter’s yield of 2.11%.

Most recently, Commercial Metals reported earnings per share at $1.44, whereas in Q1 earnings per share sat at $2.24. Most recently, the company reported a dividend yield of 1.39%, which has increased by 0.08% from last quarter’s yield of 1.31%.

Westlake saw a decrease in earnings per share from 3.1 in Q3 to $1.79 now. Its most recent dividend yield is at 1.15%, which has decreased by 0.2% from 1.35% in the previous quarter.

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

Total
0
Shares
Related Posts
Read More

Enanta Pharmaceuticals Presents New Preclinical Data For EDP-235, Its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed For The Treatment Of COVID-19 At IDWeek 2022 On October 21

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting

ENTA